Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Open AAPG dashboard ↗Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Open TLX dashboard ↗